Posts

Showing posts from October, 2025

Food Insecurity: A New Risk Factor for Cognitive Decline?

Food insecurity is linked to increased risk for dementia and cognitive impairment with or without dementia, especially in adults younger than 65 years, a new study shows. Medscape Medical News source https://www.medscape.com/viewarticle/food-insecurity-new-risk-factor-cognitive-decline-2025a1000qk5?src=rss

Head-to-Head Trial Supports New Treatment for Kids With MS

A multicenter phase 3 trial comparing ocrelizumab to fingolimod for children with MS achieved its noninferiority primary endpoint while suggesting potential safety advantages. Medscape Medical News source https://www.medscape.com/viewarticle/head-head-trial-supports-new-treatment-children-multiple-2025a1000qjn?src=rss

Most Canadian Physicians Envision Working Past Age 60 Years

Almost 30% of survey respondents expect to leave medicine in their 70s. Medscape Medical News source https://www.medscape.com/viewarticle/most-canadian-physicians-envision-working-past-age-60-years-2025a1000qhr?src=rss

Low-Dose Radiation Improved Knee OA Pain and Function

Results from only the third randomized controlled trial on the modern use of low-dose radiation therapy for osteoarthritis validated current doses used in practice. Medscape Medical News source https://www.medscape.com/viewarticle/low-dose-radiation-improved-knee-osteoarthritis-pain-and-2025a1000qhk?src=rss

Evidence on Melatonin, Ashwagandha Favorable in Children

While studies have found benefit from short-term use of melatonin and ashwagandha in children, other supplements lack evidence, and none have long-term data. Medscape Medical News source https://www.medscape.com/viewarticle/melatonin-ashwagandha-among-popular-supplements-short-term-2025a1000qha?src=rss

Oral Semaglutide Reduces CV, MALE in T2D Regardless of PAD

In a SOUL trial subanalysis, oral semaglutide lowers major adverse cardiovascular and limb events in type 2 diabetes patients with and without peripheral artery disease. Medscape Medical News source https://www.medscape.com/viewarticle/oral-semaglutide-reduces-major-adverse-cardiovascular-and-2025a1000q9a?src=rss